Shuhei Tanaka

University of Toyama
Country flagJapan

Research Interests

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Explore related searches

Articles (16)

Year:

2026

Year:

2026

Year:

2026

Year:

2026

Background Given the relatively high morbidity and death associated with transcatheter edge‐to‐edge repair for secondary mitral regurgitation, the development of optimal risk stratification models is imperative. The J‐MACS (Japanese Registry for Mechanically Assisted Circulatory Support) score is a recently developed tool designed to stratify risk in patients with advanced heart failure undergoing durable left ventricular assist device implantation. Methods Data were obtained from the OCEAN‐Mitral (Optimized Catheter Valvular Intervention–Mitral) registry on patients with secondary mitral regurgitation and left ventricular ejection fraction <50% who underwent transcatheter edge‐to‐edge repair. A newly innovated modified J‐MACS score, incorporating age, history of cardiac surgery, serum creatinine levels, and postprocedural moderate or greater tricuspid regurgitation, was calculated. Its prognostic significance regarding the primary outcome, comprising all‐cause death and heart failure–related hospitalizations, was assessed. Results A total of 2006 patients (median age, 77 years; 63% men) were included in the study. The median modified J‐MACS score was 13.7 (interquartile range, 12.0–16.2). Based on statistically calculated optimal cutoff values of 11.4 and 14.0, patients were stratified into 3 risk categories: low, moderate, and high. The 2‐year cumulative incidence of the primary outcome differed significantly among these groups (26%, 37%, and 51%, respectively; P <0.001). Risk group classification remained independently associated with the primary outcome, with an adjusted hazard ratio of 1.42 (95% CI, 1.13–1.71; P <0.001) for the intermediate risk versus low risk and 2.27 (95% CI, 1.67–2.96; P <0.001) for the high risk versus low risk. Conclusions The modified J‐MACS score demonstrated an independent association with all‐cause death and heart failure–related hospitalization following transcatheter edge‐to‐edge repair in patients with significant mitral regurgitation and systolic heart failure. Registration URL: https://upload.umin.ac.jp ; Unique Identifier: UMIN000023653.

Year:

2025

Year:

2025

Year:

2025

Background The impact of peridevice leak (PDL) at device implantation on clinical outcomes after percutaneous left atrial appendage closure (LAAC) is unknown. This study aimed to investigate the association between PDL and clinical outcomes after LAAC. Methods Using data from the OCEAN‐LAAC (Optimized Catheter Valvular Intervention‐Left Atrial Appendage Closure) Japanese multicenter registry, we examined 1397 patients who underwent LAAC between September 2019 and December 2022. The primary outcome was transient ischemic attack, ischemic stroke, or systemic embolism within 2 years of LAAC. Clinical outcomes were compared between patients with and without PDL at device implantation using Fine and Gray multivariable regression analyses and propensity score matching. Additional analyses were performed by categorizing PDL into 2 groups: ≤3 mm and >3 mm but ≤5 mm. Results Of 1397 patients who underwent LAAC, 84 (6.0%) had PDL, of whom 73 (86.9%) had ≤3 mm PDL. Patients with PDL had a larger left atrium and higher CHADS2 scores than those without PDL. Multivariable analyses showed that PDL was significantly associated with a higher risk of transient ischemic attack, ischemic stroke, or systemic embolism (adjusted subdistribution hazard ratio [sHR], 4.25 [95% CI, 1.91–9.44]; P <0.001). Even PDL ≤3 mm was independently associated with an increased risk compared with no PDL (adjusted sHR, 3.53 [95% CI, 1.37–9.04]; P =0.016). Propensity score matching analyses revealed consistent findings. Conclusions PDL was associated with a higher risk of transient ischemic attack, ischemic stroke, or systemic embolism, even PDL ≤3 mm. Therefore, it may be necessary to aim for no PDL as much as possible.

Year:

2025

Background Research on the impact of angiographically detected residual trabeculation after left atrial appendage closure (LAAC) is limited. Objectives To investigate the incidence, characteristics, and clinical implications of angiographically detected residual trabeculation after LAAC using the WATCHMAN device. Methods We analyzed 1350 consecutive patients with atrial fibrillation undergoing LAAC using the WATCHMAN device from the OCEAN‐LAAC registry, which is a prospective ongoing, multicenter Japanese registry. The inclusion criteria comprised patients who successfully underwent LAAC and whose presence or absence of residual trabeculation can be confirmed using a contrast medium. The clinical outcomes were compared between patients with and without angiographically detected residual trabeculation. Results Residual trabeculation was angiographically detected in 5.6% (75/1350 patients). At the procedure, the proportion of peri‐device leak (PDL) was significantly higher in the residual trabeculation group than in the non‐residual trabeculation group (20% vs. 5.1%, p < 0.001). However, the PDL and device‐related thrombosis at 45 days and 1 year were comparable between the two groups (37% vs. 23%, p = 0.24; 28% vs. 31%, p = 0.84; 2.1% vs. 1.4%, p = 0.50; 6.9% vs. 6.0%, p = 0.69, respectively). The 3‐year cumulative incidence of ischemic stroke, all cardiovascular death, and all‐cause death were comparable between the two groups (5.7% vs. 5.5%, log‐rank p = 0.96; 7.7% vs. 8.9%, log‐rank p = 0.34, 31.4% vs. 22.3%, log‐rank p = 0.71, respectively). Conclusion The angiographically detected residual trabeculation rate was 5.6%, and this population had a significantly higher prevalence of PDL at the procedure. However, the presence of residual trabeculation did not contribute to PDL or device‐related thrombosis at follow‐up or affect the clinical outcomes.

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2024

Year:

2024

Year:

2024

Year:

2023

Collaborators (3)

Kentaro Hayashida

Keio University School of Medicine

JAPAN
View details

Gaku Nakazawa

Kindai University Hospital

JAPAN
View details

Hiroshi Ueno

University of Toyama

JAPAN
View details